Telix Pharmaceuticals (TLX) Total Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Total Non-Current Liabilities data on file, last reported at $517.0 million in Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $517.0 million, up 28.06% year-over-year; the trailing twelve-month figure through Dec 2025 was $517.0 million (up 28.06% YoY), and the FY2025 annual result was $517.0 million, up 35.21% from the prior year.
• Total Non-Current Liabilities advanced to $517.0 million in Q4 2025 per TLX's latest filing, from $403.7 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $517.0 million in Q4 2025 and troughed at $59.9 million in Q4 2023.
• A 3-year average of $326.9 million and a median of $403.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 574.17% in 2024, then increased 28.06% in 2025.
• A 3-year view of Total Non-Current Liabilities shows it stood at $59.9 million in 2023, then jumped by 574.17% to $403.7 million in 2024, then advanced by 28.06% to $517.0 million in 2025.
• Business Quant data shows TLX's Total Non-Current Liabilities at $517.0 million in Q4 2025, $403.7 million in Q4 2024, and $59.9 million in Q4 2023.